Video

Immediate Impacts of Health-System Pharmacists as Providers

Chris Topoleski, director of federal regulatory affairs for ASHP, outlines the immediate impacts that achieving provider status would likely have on health-system pharmacists' practice.

Chris Topoleski, director of federal regulatory affairs for ASHP, outlines the immediate impacts that achieving provider status would likely have on health-system pharmacists' practice.

This video was recorded at ASHP's Summer Meeting and Exposition in June 2015.

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit: Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Related Content
Skincare foam -- Image credit: Pavel | stock.adobe.com
Published: May 22nd 2025 | Updated: May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

Gillian McGovern, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Doctor with human Eye anatomy model with magnifying glass. Eye disease, Refractive Errors, Age Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, Amblyopia, Strabismus and Healt - Image credit: Jo Panuwat D | stock.adobe.com
May 22nd 2025

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Medical Illustration Atherosclerosis, Cholesterol Plaque, Blood Clot in Artery, Cardiovascular Disease.
May 22nd 2025

Risk of Cardiovascular Event Increases With Rising Lipoprotein(a) Levels in Patients With ASCVD

Luke Halpern, Assistant Editor
Young child having his height measured by his mother -- Image credit: DimaBerlin | stock.adobe.com
May 22nd 2025

Sogroya Observed as Efficacious and Well-Tolerated in Children With Growth Disorders

Gillian McGovern, Associate Editor